May 1, 2026—Archimed Diagnostics, part of private equity health care firm Archimed, has acquired Stago, with global investment group La Caisse participating as a minority shareholder. Stago aims to “strengthen its investment capabilities, accelerate its innovation projects, intensify its international expansion, and leverage its scientific expertise in operational and commercial performance” under the new ownership, according to a statement from Stago.
“Archimed’s diagnostics expertise is key for accelerating the efficient rollout of a major, new generation of Stago products,” Philippe Barroux, Stago’s CEO-elect, said in an Archimed release. “This partnership is all about reigniting innovation at Stago.”
Archimed aims to expand sales and profits by building on products in developed and developing nations.